Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-06-01 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the board meetings approving the repurchase plans, the amount and price limits, and the actual shares repurchased up to May 31, 2022. The document includes compliance with relevant laws and stock exchange regulations, and it is titled as a progress announcement on share repurchase. The length is 2171 characters, which is relatively short and focused on the update of the share buyback activity rather than a full financial report or detailed analysis. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2022-06-01 Chinese
关于SAL0112片获得药品临床试验申请受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (SAL0112). It contains no financial data, no regulatory filings related to financial performance, no management or board changes, no voting results, no earnings or annual reports, and no detailed financial or strategic presentations. The document is an announcement of a regulatory approval event related to drug development, which does not fit into the financial or corporate filing categories such as 10-K, IR, ER, or MDA. It is a regulatory announcement about a clinical trial acceptance, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-05-30 Chinese
关于SAL0108临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a clinical trial for a pharmaceutical product (SAL0108). It provides details about the clinical trial phase and future expectations but does not contain financial data, regulatory certifications, or detailed financial reports. It is a regulatory announcement about clinical development progress, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not a report publication announcement or certification. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-05-26 Chinese
关于JK08提交CTA及JK07美国临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding clinical trial progress for two drug candidates JK08 and JK07. It includes details about submission of clinical trial applications (CTA) and early clinical trial data. The text is relatively short (1876 characters) and focuses on clinical development updates rather than financial results or regulatory filings. There is no indication of financial statements, audit information, or shareholder meeting materials. The document is an announcement of clinical trial progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like earnings release or capital update.
2022-05-23 Chinese
关于使用部分闲置募集资金现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the purchase of a financial product using idle raised funds, risk control measures, and compliance with regulatory requirements. The document is relatively short (1791 characters) and serves as a disclosure or progress update rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis. This fits the category of a Capital/Financing Update (CAP), as it relates to the use and management of raised capital funds.
2022-05-20 Chinese
关于增设募集资金专户暨签订募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the establishment of a special account for raised funds and the signing of a tripartite supervision agreement related to fundraising. It details the approval by the China Securities Regulatory Commission for a non-public stock issuance, the amount raised, and the use of the funds. It also describes the supervisory agreement between the company, the bank, and the sponsor. The document is relatively short (2209 characters) and focuses on the fundraising process and regulatory compliance rather than presenting financial statements or detailed financial performance. This fits the description of a Capital/Financing Update (CAP) as it provides updates on company fundraising activities and capital management. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-05-16 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.